Rockwell Medical (RMTI) Total Non-Current Liabilities (2010 - 2025)
Rockwell Medical's (RMTI) quarterly Total Non-Current Liabilities came in at $20.2 million in Q4 2025, down 21.3% YoY from $25.6 million in Q4 2024, and down 1.48% on a QoQ basis from $20.5 million in Q3 2025.
Rockwell Medical (RMTI) Total Non-Current Liabilities (2010 - 2025) Analysis & Trends
Rockwell Medical (RMTI) has 11 years of Total Non-Current Liabilities data on file, last reported at $20.2 million in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 21.3% year-over-year to $20.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.2 million (down 21.3% YoY) and the FY2025 annual result came in at $20.2 million, down 21.3% from the prior year.
- Total Non-Current Liabilities retreated to $20.2 million in Q4 2025, from $20.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $46.0 million in Q4 2021 to a low of $20.2 million in Q4 2025.
- A 5-year average of $30.1 million and a median of $28.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities sank 33.89% — and 2024, when it rose 7.7%.
- Tracing RMTI's Total Non-Current Liabilities over 5 years: stood at $46.0 million in 2021, then slipped by 29.32% to $32.5 million in 2022, then retreated by 5.11% to $30.9 million in 2023, then fell by 16.99% to $25.6 million in 2024, then retreated by 21.3% to $20.2 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $20.2 million (Q4 2025), $20.5 million (Q3 2025), and $22.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Rockwell Medical | 30.62 Mn | 5.82 Mn | 3.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20.16 Mn |
| Sep 30, 2025 | 20.47 Mn |
| Jun 30, 2025 | 22.22 Mn |
| Mar 31, 2025 | 21.94 Mn |
| Dec 31, 2024 | 25.62 Mn |
| Sep 30, 2024 | 27.94 Mn |
| Jun 30, 2024 | 29.52 Mn |
| Mar 31, 2024 | 30.07 Mn |
| Dec 31, 2023 | 30.87 Mn |
| Sep 30, 2023 | 28.59 Mn |
| Jun 30, 2023 | 28.50 Mn |
| Mar 31, 2023 | 27.92 Mn |
| Dec 31, 2022 | 32.53 Mn |
| Sep 30, 2022 | 38.04 Mn |
| Jun 30, 2022 | 38.96 Mn |
| Mar 31, 2022 | 42.23 Mn |
| Dec 31, 2021 | 46.03 Mn |
| Dec 31, 2020 | 43.58 Mn |
| Sep 30, 2014 | 19.65 Mn |
| Jun 30, 2014 | 21.66 Mn |